Publications by authors named "Lambros M"

Objective: Previous studies have reported that patients with Multiple Sclerosis (MS) face cognitive difficulties. Much less, however, is known about their language abilities. The present study aims to provide a clear view of the language abilities of adults with MS, considering their cognitive skills and the type of the disorder.

View Article and Find Full Text PDF
Article Synopsis
  • - PARP inhibitors show promise in treating castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects, but the reasons behind resistance are not completely understood.
  • - A study from the TOPARP-B trial found that 79% of BRCA2/PALB2-mutated tumors exhibited reversion mutations at the end of treatment, with many related to POLQ-mediated DNA repair mechanisms.
  • - In cases of BRCA2 homozygous deletions, rare subclones lacking the BRCA2 deletion are selected for after PARP inhibitor treatment, indicating the necessity for restored HRR function in developing resistance.
View Article and Find Full Text PDF

Using Gruppen et al's model, this study investigated experiences of the LE from the perspectives of both URM and non-URM students at a medical school in New York City. In examining experiences of the organizational, social, and physical domains of the LE, we sought to explore the symbolic and experiential links across domains and identify concrete needs for improvement. Institutional structures and policies, features of the built environment, and social relationships that put learning first and generated a sense of community were highly valued.

View Article and Find Full Text PDF

Oral mucositis is a common side effect of cancer treatment, and in particular of treatment with the mTORC1 inhibitor everolimus. Current treatment methods are not efficient enough and a better understanding of the causes and mechanisms behind oral mucositis is necessary to find potential therapeutic targets. Here, we treated an organotypic 3D oral mucosal tissue model consisting of human keratinocytes grown on top of human fibroblasts with a high or low dose of everolimus for 40 or 60 h and investigated (1) the effect of everolimus on microscopic sections of the 3D cell culture for evidence of morphologic changes and (2) changes in the transcriptome by high throughput RNA-Seq analysis.

View Article and Find Full Text PDF

Epigenetic regulatory mechanisms allow multicellular organisms to develop distinct specialized cell identities despite having the same total genome. Cell-fate choices are based on gene expression programs and environmental cues that cells experience during embryonic development, and are usually maintained throughout the life of the organism despite new environmental cues. The evolutionarily conserved Polycomb group (PcG) proteins form Polycomb Repressive Complexes that help orchestrate these developmental choices.

View Article and Find Full Text PDF

Citric acid, a tricarboxylic acid, has found wide application in the chemical and pharmaceutical industry due to its biocompatibility, versatility, and green, environmentally friendly chemistry. This review emphasizes the pharmaceutical uses of citric acid as a strategic ingredient in drug formulation while focusing on the impact of its physicochemical properties. The functionality of citric acid is due to its three carboxylic groups and one hydroxyl group.

View Article and Find Full Text PDF
Article Synopsis
  • - Researchers found that HER3, a protein often overexpressed in aggressive prostate cancer, is linked to faster progression to castration resistance and lower survival rates.
  • - The study identified that NRG1, a ligand for HER3, is primarily produced by certain immune cells in the tumor environment, and its presence promotes cancer cell growth.
  • - Targeting HER3 with specific therapies, like the antibody-drug conjugate U3-1402, shows promise in fighting HER3-positive prostate cancer, suggesting the need for further clinical trials.
View Article and Find Full Text PDF

Generalists and specialists are types of strategies individuals can employ that can evolve in fluctuating environments depending on the extremity and periodicity of the fluctuation. To evaluate whether the evolution of specialists or generalists occurs under environmental fluctuation regimes with different levels of periodicity, 24 populations of underwent laboratory evolution with temperatures alternating between 15 and 43°C in three fluctuation regimes: two periodic regimes dependent on culture's cell density and one random (non-periodic) regime with no such dependency, serving as a control. To investigate contingencies on the genetic background, we seeded our experiment with two different strains.

View Article and Find Full Text PDF
Article Synopsis
  • Better blood tests are needed for metastatic castration-resistant prostate cancer (mCRPC) to guide treatment decisions, and low-pass whole-genome sequencing (lpWGS) of circulating tumor DNA (ctDNA) shows promise in providing insights into mCRPC behavior.
  • The study examined plasma lpWGS data from 188 mCRPC patients undergoing two phase 3 clinical trials, with an aim to assess its prognostic value and its ability to correlate with treatment response.
  • Findings suggest that plasma tumor fraction is a strong predictor of overall survival and is more informative than existing biomarkers, while genomic instability indicated by large-scale transition scores was linked to previous treatments but not to others like taxane or radiation therapy.*
View Article and Find Full Text PDF
Article Synopsis
  • Endocrine resistance in advanced prostate cancer is driven by proteins like AR-V7, with JMJD6 being a key regulator of its production.
  • The study found that increasing levels of JMJD6 correlate with higher AR-V7 levels and reduced survival rates in patients.
  • JMJD6 knockdown led to reduced prostate cancer cell growth and less AR-V7, suggesting that targeting JMJD6 could be a promising therapy for combating prostate cancer.
View Article and Find Full Text PDF
Article Synopsis
  • CD38 is an ectoenzyme that contributes to the production of adenosine, which plays a role in how tumors evade the immune system, particularly in prostate cancer.* -
  • The study aimed to analyze CD38 expression in prostate cancer cells and immune cells, using samples from multiple patient cohorts to link this expression to clinical outcomes.* -
  • Findings showed that higher CD38 mRNA levels in metastatic castration-resistant prostate cancer (mCRPC) were linked to activated immune signaling pathways, specifically involving certain interleukins.*
View Article and Find Full Text PDF

Purpose: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte (TIL) data.

Experimental Design: Patients with mCRPC consented to the molecular analyses of diagnostic and mCRPC biopsies.

View Article and Find Full Text PDF

has been historically and is currently a threat to global public health. First-line antibiotics have been effective but proven to be burdensome as they have many potential adverse side effects. There has been a recent increase in the number of active tuberculosis (TB) cases due to a prevalence of multidrug and extensively drug-resistant strains of , and an increasing number of highly susceptible people such as those with Type 2 Diabetes (T2DM) and human immunodeficiency virus (HIV) infection.

View Article and Find Full Text PDF
Article Synopsis
  • Transcriptional dysregulation is a key feature of prostate cancer, involving altered chromatin interactions between various genomic elements.
  • The research identified how structural proteins and master transcription factors, such as the androgen receptor, enhance or alter the regulation of important PCa genes.
  • The findings suggest that changes in genome organization significantly contribute to abnormal transcription regulation, particularly in the context of specific genetic risk factors and gene fusions in PCa.
View Article and Find Full Text PDF
Article Synopsis
  • About 50% of patients with metastatic castration-resistant prostate cancer (mCRPC) have issues with the PI3K/AKT/mTOR pathway due to lost PTEN, and combining treatments that target the androgen receptor and AKT could help them.
  • In a study, mCRPC patients who didn’t respond to previous treatments received different doses of capivasertib along with enzalutamide to evaluate safety and effectiveness.
  • The recommended dose of capivasertib was found to be 400 mg twice daily, with manageable side effects and some patients showing significant positive responses, particularly those with specific genetic characteristics.
View Article and Find Full Text PDF
Article Synopsis
  • - The traditional classification of human cancers focuses on tissue origin and histology, but this approach doesn't fully explain the varied clinical outcomes of different cancers.
  • - Advances in molecular characterization, especially through next-generation sequencing, have revealed the genetic diversity within cancers, prompting interest in using circulating tumor cells (CTCs) as a less invasive alternative to tissue biopsies.
  • - CTCs have shown prognostic value in several types of cancer and may offer a more effective way to analyze tumor genetics and evolution; however, whether these blood-based methods will fully replace traditional biopsies is still uncertain.
View Article and Find Full Text PDF

Background: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility.

Objective: To elucidate PC PSMA expression and associate this with defective DNA damage repair (DDR).

Design, Setting, And Participants: Membranous PSMA (mPSMA) expression was scored immunohistochemically from metastatic castration-resistant PC (mCRPC) and matching, same-patient, diagnostic biopsies, and correlated with next-generation sequencing (NGS) and clinical outcome data.

View Article and Find Full Text PDF

Background: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC counts and biopsy AR-V7 protein expression.

Objective: To determine the reproducibility of AdnaTest CTC AR-V7 testing, and associations with clinical characteristics, CellSearch CTC counts, tumour biopsy AR-V7 protein expression and overall survival (OS).

View Article and Find Full Text PDF

Background: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection.

Methods: Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IHC or microsatellite instability (MSI) by PCR in 127 APC biopsies from 124 patients (Royal Marsden [RMH] cohort); MSI by targeted panel next-generation sequencing (MSINGS) was then evaluated in the same cohort and in 254 APC samples from the Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF). Whole exome sequencing (WES) data from this latter cohort were analyzed for pathogenic MMR gene variants, mutational load, and mutational signatures.

View Article and Find Full Text PDF

Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency. We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic prostate cancer, allow precise gene copy-number calls, and study disease heterogeneity. Apheresis was well tolerated and allowed the separation of large numbers of CTCs; the average CTC yield from 7.

View Article and Find Full Text PDF

Frequently, the number of circulating tumor cells (CTC) isolated in 7.5 mL of blood is too small to reliably determine tumor heterogeneity and to be representative as a "liquid biopsy". In the EU FP7 program CTCTrap, we aimed to validate and optimize the recently introduced Diagnostic LeukApheresis (DLA) to screen liters of blood.

View Article and Find Full Text PDF

The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in homologous recombination. The cytotoxicity of PARP inhibitors depends on PARP trapping, the formation of non-covalent protein-DNA adducts composed of inhibited PARP1 bound to DNA lesions of unclear origins. To address the nature of such lesions and the cellular consequences of PARP trapping, we undertook three CRISPR (clustered regularly interspersed palindromic repeats) screens to identify genes and pathways that mediate cellular resistance to olaparib, a clinically approved PARP inhibitor.

View Article and Find Full Text PDF